自杀的flecainide:一个案例报告和文献的审查
Angelo Montana1, Fabrizio Lo Faro1, Chiara Turchi1
1Department of Biomedical Sciences and Public Health, Università Politecnica Delle Marche, 60126, Ancona, Italy.
Forensic science, medicine, and pathology
|March 7, 2026
概括
这项法医案例研究发现,一名医生患有致命的弗莱卡尼尼德中毒. 药物遗传学揭示了 CYP3A5 低代谢器基因型,这有助于毒性,并突出了对个性化药物的需求.
科学领域:
- 法医毒理学 法医毒理学
- 临床药理学 临床药理学
- 药物遗传学 药物遗传学
背景情况:
- 弗莱卡尼德是一种抗心律失常药物,安全边缘很窄.
- 致命的毒性可能会发生,需要谨慎管理.
- 药物遗传学在药物代谢和毒性方面发挥着作用.
研究的目的:
- 为了呈现一个致命的 flecainide 中毒的法医案例.
- 调查药物遗传学在飞胺代谢和毒性中的作用.
- 审查有关弗莱卡尼德中毒的文献.
主要方法:
- 死后检查,包括组织学和毒理学.
- 在血液和尿液中量化flecainide.
- 对CYP2D6和CYP3A5酶的基因定型.
- 文献综述. 这是一个文献综述.
主要成果:
- 测量了3.411毫克/升 (中心) 和2.962毫克/升 (外围) 的飞胺度.
- 确定了一个CYP3A5 * 3 / * 3低代谢器基因型,表明药物清除减少.
- 组织学显示轻度冠状动脉狭窄和心脏性休克迹象.
结论:
- 由于死后的变化和个体的新陈代谢,诊断致命的flekainide中毒是复杂的.
- 整合药物遗传数据可以改善毒理学解释.
- 个性化治疗策略可以减轻flekainide的毒性风险.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Dysrhythmias III: Characteristics of Dysrhythmias
709
Dysrhythmias, also known as arrhythmias, are irregular heart rhythms that result from abnormal electrical activity in the heart, affecting its ability to circulate blood efficiently. Tachyarrhythmias, a subset of dysrhythmias, are characterized by abnormally fast heart rates exceeding 100 beats per minute. Here are some types of tachyarrhythmias with their distinct ECG features:Sinus Tachycardia:Sinus tachycardia presents a regular heart rhythm with an increased rate of 101-180 beats per...
709
Dysrhythmias V: Evaluating Dysrhythmias
428
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
428
Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K


